Objectives. To determine the rate and identify risk factors of Pneumocystis jirovecii (P. jirovecii) colonization among patients with systemic autoimmune diseases.
Introduction
Pneumonia caused by the opportunistic fungus Pneumocystis jirovecii (P. jirovecii) is a major cause of morbidity and mortality in immunocompromised hosts. Despite the availability of effective medication for prophylaxis and treatment, mortality is reported to be between 15 and 40%, and is particularly high in patients with immunodepression other than AIDS [1] .
The pathogenesis of the disease in humans remains undetermined. The two main hypotheses are a reactivation of earlier colonization and a de novo infection [2] . In patients with systemic autoimmune disease (SAD), Pneumocystis pneumonia (PcP) is not rare, and in a study on 78 HIV-negative patients with PcP, SAD represented the second most common underlying disease in patients with PcP [3] . Nevertheless, the true incidence of PcP in SAD is difficult to determine and can vary according to the disease and the presence of immunosuppressive treatment. For example, the incidence of PcP varies between 2% in patients with systemic lupus and 8-12% in patients with Wegener's disease. PcP usually has a more rapid onset and is more severe than the pulmonary manifestations caused by SAD. In most cases, PcP occurs at the beginning of the treatment and mostly with >20 mg of daily corticosteroids [4] . PcP in SAD can be difficult to diagnose as it can mimic pulmonary involvement of the disease. Furthermore, diagnosis is frequently delayed as few Pneumocystis cysts are present on bronchoalveolar lavage. Mortality is higher than that in HIV-positive patients [5] . For HIV-positive patients, there are clear clinical guidelines on prophylaxis treatment and these have helped to dramatically reduce morbidity and mortality from PcP in this population. In contrast, there are as yet no guidelines on PcP prophylaxis in SAD patients. PcP prophylaxis is now used in the majority of patients with Wegener's disease treated with an intensive course of CYC, as PcP occurred in a high percentage of these patients. There are no other known determinate risk factors for PcP in this population, unlike the CD4 count in HIV patients. The physiopathology of PcP includes colonization before PcP development, and therefore, a colonization study in immunodeficient patients could be an interesting tool for PcP prevention.
During the past decade, molecular techniques such as PCR assays for detecting P. jirovecii have been developed, making it possible to detect colonized subjects [6, 7] . The presence of P. jirovecii in subjects without signs of PcP is currently considered as colonization [6] . Whereas the existence of permanent colonization in healthy subjects remains controversial, high rates of P. jirovecii colonization have been reported in patients with AIDS or chronic obstructive pulmonary disease (COPD) [6] . Few studies have investigated P. jirovecii PCR values in SAD. Even though a positive P. jirovecii PCR in a respiratory sample can provide evidence of colonization, it can sometimes reveal PcP. We conducted a retrospective study of P. jirovecii PCR testing of respiratory samples in immunodeficient patients with SAD presenting respiratory symptoms: over a 10-year period, 73 immunodeficient patients with SAD had respiratory samples collected for pulmonary symptoms. In these 73 patients, P. jirovecii PCR was positive in 20 cases: 9 patients presented PcP (as P. jirovecii was the sole pathogen found, and pulmonary symptoms resolved on PcP treatment alone); in the other patients, positive P. jirovecii PCR was considered as colonization [8] . The actual prevalence of colonization in patients with SAD is unknown, as is the risk of PcP in colonized patients. We carried out a prospective observational study in patients with SAD in a single centre, in order to determine the prevalence of and risk factors for P. jirovecii colonization in this population as well as the risk of PcP development in colonized subjects.
Patients and methods

Patients and control subjects
We carried out a prospective observational study from January to March 2008 in an Internal Medicine Department of Lille University Hospital. Every week during this period, five patients admitted to a day clinical unit were randomly selected to participate in the study. All participants gave informed consent before being included. The inclusion criteria were: age, >18 years and SAD. The exclusion criteria were: HIV-positive patients; acute respiratory symptoms; active neoplasm; and RA.
The diagnostic criteria for the different SADs were those currently used. Induced sputum specimens were obtained as follows: after hypertonic saline solution inhalation for 15 min, induced sputum was collected by a physiotherapist. The sample was transported rapidly on ice to the laboratory, where the presence of P. jirovecii was evaluated by P. jirovecii PCR.
A population of healthy subjects from the same region, derived from the Eurocarinii European network (5th FP, QLK2-CT-2000-01369), was used as a control group. This group had no history of hospitalization in the year before the study and had not been diagnosed with or suspected of having chronic lung disease, active neoplasm or immunosuppression of any cause.
This study was approved by the local ethics committee (Comité de Protection des Personnes, Nord-Ouest, Lille, France) in accordance with current French legislation and all patients and controls gave their informed consent.
Data collection
For all patients, clinical and laboratory data were recorded, including age, sex, type of SAD, presence of chronic pulmonary disease and of anti-Pneumocystis medication. Daily and total cumulated doses of corticosteroids (CS) and any other immunosuppressive medications were recorded for diagnosis of SAD. The number of hospitalizations during the 12 months before the study and the presence of active smoking were analysed. Total lymphocyte and CD4 + T-cell counts and gammaglobulin levels were recorded on inclusion. For control subjects, age, sex, pulmonary disease, active smoking, respiratory function test, lymphocyte counts and current treatment were analysed.
DNA extraction, PCR detection and identification of P. jirovecii DNA was extracted from the pellet of induced sputum using QIAamp DNA mini kit (Qiagen, Courtaboeuf, France) according to the manufacturer's tissue protocol. PCR detection of Pneumocystis DNA was based on the method published by Wakefield, using primers pAZ102-X and pAZ102-Y, amplifying a portion of the large subunit of the mitochondrial ribosomal RNA gene (mt LSU rRNA gene) [9] . Negative controls were included in each experiment, in both DNA extraction and amplification, to monitor possible contamination. DNA extraction and PCR were performed in laminar flow, and disposable tips, tubes and aliquot reagents were used to avoid contamination. A sample of positive P. jirovecii DNA obtained from a patient with positive microscopic examination was used as a positive control in each experiment. Moreover, PCR was performed for each sample in duplicate. PCR products were identified as P. jirovecii by hybridization with a P. jirovecii-specific oligonucleotide probe, as previously described [10] . Results were expressed as either positive, if the presence of P. jirovecii DNA was detected, or negative.
Follow-up
All SAD subjects with P. jirovecii-positive PCR were followed up at 3-month intervals for a period of 12 months. The presence of PcP was analysed using clinical and radiological criteria. During the follow-up, lymphocyte counts, CS amounts and immunosuppressor medication, as well as trimethoprim-sulphamethoxazole, were noted every 3 months.
Statistical analysis
Quantitative variables with normal distribution were expressed as medians with ranges and compared by analysis of variance (ANOVA) or Mann-Whitney test depending on their distribution. Qualitative variables were expressed as a percentage and compared by Chi-squared or Fisher's exact test.
Different characteristics were compared first between SAD patients and controls. Then, a comparison was made between P. jirovecii-positive PCR and P. jiroveciinegative PCR SAD patients. A multivariate logistic regression analysis was performed using the variables with P < 0.1 in univariate analysis among patients with SAD. P < 0.05 was defined as statistically significant.
Results
Prevalence of P. jirovecii colonization Seventy patients selected among 900 SAD patients during a 3-month period were included in this prospective study. P. jirovecii PCR could be performed in 67 patients, none of whom had respiratory or general signs compatible with current PcP infection.
Among the 67 patients, 15 (22%) had SLE, 17 (25%) had inflammatory myositis, 15 (22%) had SSc, 15 (22%) had different systemic vasculitis and the remaining five had other SAD. Trimethoprim-sulphamethoxazole was prescribed at the time of inclusion for nine patients: in five patients because of a low blood CD4 + T-cell count (<200/mm 3 ) and in four patients because of vasculitis with pulmonary disease associated with CYC treatment. Eleven (16%) patients with SAD had P. jirovecii-positive PCR, whereas only two (7%) subjects were positive among the healthy control group (Table 1) . The prevalence of P. jirovecii-positive PCR in patients with SAD compared with healthy controls was not statistically significant (16 vs 7%; P = 0.3). Nevertheless, because there was a significantly higher proportion of men to women in the control group compared with the SAD group (P < 0.0001), we compared P. jirovecii prevalence stratified on gender. We found a significantly higher prevalence of P. jirovecii-positive PCR in male SAD patients than in male controls (men: 7/21 vs 1/21; P < 0.001) ( Table 2) ; there was no significant difference between women in the two groups, with a low prevalence in each case.
Risk factors for P. jirovecii colonization in patients with SAD In order to evaluate risk factors for P. jirovecii colonization in SAD patients, P. jirovecii-positive PCR patients were compared with non-colonized patients (Table 3 ). In univariate analysis, P. jirovecii-positive PCR patients were more often men (64 vs 25%), had lower CD4 + T-cell counts (528 vs 765/mm 3 ) and their daily (25 vs 15 mg) and total CS amounts (9.4 vs 7 g) were higher (Table 3) . MTX was more frequently associated with P. jiroveciipositive PCR (49 vs 22%). A higher proportion of P. jirovecii-negative PCR patients than P. jirovecii-positive PCR had active smoking (39 vs 9%) and trimethoprim- Values are mean (S.D.) or frequency (%). *P < 0.05.
www.rheumatology.oxfordjournals.org sulphamethoxazole medication (23 vs 9%), whereas the presence of chronic pulmonary disease (23 vs 18%) was similar in both groups. Nevertheless, the sole statistically significant difference between the P. jirovecii-positive and P. jirovecii-negative PCR patients was the higher proportion of men in the P. jirovecii-positive PCR group (P = 0.03).
To try to account for the male predominance among P. jirovecii-positive PCR patients, and because of the limited number of patients for multivariate stratified analysis by gender (men: 7 SAD vs 14 controls; women: 5 SAD vs 42 controls), a comparison of patient characteristics was carried out according to the gender of whole SAD group (Table 4) . In univariate analysis, the total lymphocyte level was significantly lower in the male subgroup than in the female subgroup (800 vs 1450/mm 3 ; P = 0.01), the daily CS dose was higher (30 vs 15 mg; P = 0.01) and, as previously noted, P. jirovecii-positive PCR was significantly more frequent (33 vs 9%; P = 0.03; Table 3 ). In nested multivariate analysis, the difference in PCR colonization with regard to gender disappeared after adjustment for daily CS and lymphocyte counts with an odds ratio (OR) that fell from 5.2 (95% CI 1.3, 20.2) to 4 (95% CI 0. 8, 19) . This difference in colonization between the genders was thus largely explained by higher daily CS (OR = 1.6; 95% CI 1.1, 2.3) and lower total lymphocyte counts (OR = 0.9; 95% CI 0.8, 0.99), which were the only differences that remained significant between the genders (Table 5 ).
PcP occurrence in P. jirovecii PCR-positive patients
No PcP case was observed among the 11 SAD patients with P. jirovecii-positive PCR at 12 months of follow-up.
One patient died at 6 months of follow-up from known cardiac disease. One patient presented clinical signs of infectious pulmonary disease at 6 months of follow-up, but both P. jirovecii PCR and P. jirovecii microscopic study were negative on bronchoalveolar lavage and this patient did not receive anti-Pneumocystis treatment.
Whereas no difference was seen in the number of immunosuppressors and the lymphocyte counts at different times of follow-up, CS daily amounts were significantly different at 9 and 12 months compared with the start of the study (P < 0.05) ( Table 6 ). Whereas only one patient was on trimethoprim-sulphamethoxazole at the start Values are medians with inter-quartiles or numbers with percentages. *P < 0.05. of the study, the drug was used in four patients at 3 months and in two patients at the follow-up end-point (Table 6) . P. jirovecii PCR was carried out in 3 of these 11 PCR-positive patients: at 6 months in 2 cases and at 9 months in 1 case, and was negative in all cases, whereas none of these patients was on trimethoprim-sulphamethoxazole medication. Nevertheless, the persistence of P. jirovecii colonization in the whole group could not be ascertained, as P. jirovecii PCR was not carried out in all patients.
PcP occurrence in P. jirovecii PCR-negative patients No PcP case occurred in P. jirovecii-negative patients during the year after the beginning of the study. Thirteen patients among 56 P. jirovecii-negative patients were hospitalized during the year of follow-up for infectious pulmonary disease, but P. jirovecii PCR was negative in all cases and none of these patients was treated with trimethoprim-sulphamethoxazole.
Discussion
Our study shows a high level of P. jirovecii colonization among SAD patients (16%), predominantly in men. The only previous study on P. jirovecii colonization in patients with SAD, which included only patients with RA, estimated colonization to be 11% [11] . The higher level of immunosuppression in our male patients could account for the higher rate of colonization in our study.
In the general population, P. jirovecii colonization is usually absent, although two studies showed a prevalence rate of 8 and 20%, respectively [12, 13] . These two studies were conducted in France and Spain on hospital workers and one of the studies found differences in the prevalence of colonization according to the geographical location [13] . Another study, in HIV-positive subjects, showed a lower colonization rate in the residents of Los Angeles compared with other cities in the USA [14] . Geographical location and differences in exposure as well as different PCR techniques might at least partially explain the differences between the studies. For this reason, we used a control group from our geographical region. We found that P. jirovecii colonization was twice as frequent in the SAD patients compared with the control group. Because of the statistical difference between the two groups in terms of the proportion of men, we conducted a comparison stratified by gender, which revealed a significant difference in P. jirovecii colonization in male SAD patients compared with controls (P < 0.0001). Values are medians (inter-quartile range) or n (%). *P < 0.05. Male gender was the only risk factor identified in this study. But when we analysed in nested models the difference in characteristics between male and female patients with SAD, the difference in terms of P. jirovecii colonization was mainly explained by the higher level of induced immunosuppression in the male patients, as suggested by lymphocyte counts and CS amounts.
The sex ratio of P. jirovecii-colonized patients in other diseases is usually close to one, except in some studies of HIV-positive patients where men are usually underrepresented [14] . A study on PcP in SAD patients found a significant male prevalence [15] . Males with SAD could have a more severe disease, which could explain the higher level of induced immunodepression, but in our study different SADs were included and it was not possible to compare disease severity [16, 17] . However, some authors have suggested that male gender may be a risk factor for poor prognosis in SAD [18] .
CS seems to be a risk factor for P. jirovecii colonization. In animal models, prolonged CS administration is usually used to induce PcP [19] . In humans, Maskell et al. [20] . detected P. jirovecii in 8 (44%) patients with CS, compared with 9 (12%) of 75 untreated patients. Helweg-Larsen et al. [21] reported that 75% of P. jirovecii-colonized patients had received CS against only 13% of non-colonized patients, whereas Mori et al. [11] found that among PCR-positive patients with RA, only 50% were receiving CS.
Few studies have analysed total lymphocyte counts in HIV-negative P. jirovecii-colonized patients. Normal lymphocyte levels have been reported in healthy colonized subjects [13] , and no differences were noted in patients with RA [11] , whereas an increase in lymphocyte counts was reported in COPD [22] . On the other hand, whereas CD4 + T-cell count is a well-recognized predictive factor for PcP in HIV-positive patients, its value for predicting colonization in these patients is debatable. Leigh et al. [23] found rates of colonization of 10% in patients with a CD4 + T cell count of <400/mm 3 and 40% in those with a cell count of <60 /mm 3 , but other studies did not find any association with CD4 + T levels in HIV-positive patients [14, 24, 25] . In a study on HIV-negative patients, 30% of colonized patients had a CD4 + T-cell count of <400/mm 3 [26] . Even though total lymphocyte and CD4 + T-cell counts were lower in our P. jirovecii-positive PCR patients, only the difference in total lymphocyte levels was statistically significant. In an SAD population, the qualitative effect of immunosuppressive agents on lymphocyte function may be a more significant factor than the CD4 + T-cell count [27] . All other known factors of P. jirovecii colonization were analysed in the present study, but none of them appeared to be a specific risk factor. The presence of chronic pulmonary disease, particularly COPD, is a risk factor for P. jirovecii colonization. Colonization rates vary from study to study, ranging from 6 to 40%, and could be correlated with the severity of the pulmonary disease [28] [29] [30] . Active smoking was suspected of being a risk factor for colonization in a study on HIV-positive patients [14] , and in 80 patients with chronic pulmonary disease the risk was higher among smokers [30] . A low serum gammaglobulin level was noted to be a risk factor for PcP in two studies of patients with SAD, as well as in children with congenital immunodeficiency [31, 32] . In one study, MTX therapy was suspected of being involved in the occurrence of PcP cases, even in the absence of CS, and all colonized patients with RA were receiving MTX [11] . Among our P. jirovecii-positive PCR patients, MTX was present in 49% of patients on immunosuppressors vs 22% in the P. jirovecii-negative PCR group.
In our P. jirovecii-positive PCR patients, no PcP had occurred at 12 months of follow-up. Nevertheless, the persistence of colonization was not assessed by PCR assay in 8/11 patients, and three patients were found to be no longer colonized during follow-up. Among 164 healthy hospital care workers, 8% were colonized, but this colonization was transient (3-10 weeks) [12] . On the other hand, in our patients CS were rapidly decreased, both in the three patients followed by PCR and in the whole group with P. jirovecii-positive PCR, and CS daily amounts were significantly lower during follow-up. Therefore, the absence of PcP in P. jirovecii-positive PCR patients might well be explained by the decrease in treatment-induced immunodepression during the follow-up. The development of PcP from colonization and transmission of P. jirovecii from colonized patients have not yet been ascertained. Among HIV-positive P. jirovecii-colonized patients, 12/19 P. jiroveciipositive PCR patients developed PcP vs 4/31 of Values are medians (inter-quartile range) or n (%). *P < 0.05, M9 vs M0; **P < 0.05, M12 vs M0.
P. jirovecii-negative PCR patients [33] . Three out of nine colonized patients with RA developed PcP, but 45% of these Japanese patients had pulmonary disease vs 18% in our study [11, 13] . The use of trimethoprimsulphamethoxazole in some patients in our study (5/9 colonized patients in another study [34] ), meant that we were to assess the risk of PcP from colonization in patients with SAD. Whereas the prophylactic effectiveness of trimethoprim-sulphamethoxazole in HIV-positive patients is close to 100% in preventing PcP, it does not seem to play a role in P. jirovecii colonization [23, 25] . Oropharyngeal washing could be another useful method to detect P. jirovecii. Nevertheless, only induced sputa were used in this study, as it makes possible a specimen of alveolar origin. Moreover, in our experience, it could be necessary to apply nested PCR on oropharyngeal samples in order to detect P. jirovecii colonization, and this kind of PCR assay is more at risk of crosscontamination [7, 12] .
Concerning the risk of transmission of P. jirovecii from colonized individuals, studies using animal models have shown that immunodeficient Pneumocystis-free mice can develop PcP when they are exposed to colonized mice. Likewise, two teams found that healthy host-to-healthy host transmission of Pneumocystis murina can occur [35, 36] . In a study using histology and molecular markers, the authors showed that P. jirovecii organisms are able to replicate in the lungs of immunocompetent hosts [35] . More recently, other authors have reported genotypic evidence of P. jirovecii transmission from colonized grandparents to their infant granddaughter [37] . These findings support the hypothesis of the role of colonized carriers in the airborne circulation of P. jirovecii in human populations, even if healthy carriers are often only transiently infected by the fungus. Two studies have shown a high prevalence of colonization among healthy hospital care workers [8, 9] . In a study on hospital care workers in contact with PcP patients, 4/11 contact individuals were secondarily colonized by P. jirovecii, compared with none of the controls [38] . In another study, P. jirovecii DNA was more often found in hospital care workers in contact with PcP patients than in a control group [39] . On the whole, these data support the notion of a PcP nosocomial risk for susceptible patients. The implementation of specific prevention measures, such as droplet isolation, should therefore be considered.
Another consequence of P. jirovecii colonization could be the persistent inflammatory reaction; in this context, higher lymphocyte and CD4 + T-cell counts as well as elevated levels of inflammatory cytokines (TNF-a, IL-6 and IL-8) have been noted in colonized patients with COPD [22, 40] . To our knowledge, this is the first prospective study on P. jirovecii colonization in SAD patients, other than those with RA, and the outcome after a 1-year follow-up. The rate of colonization was high (16%). The other interesting result of this study is CSs therapy and lymphocyte counts as risk factors for colonization. The statistical power of our population was low, which could account for the lack of significant results in the statistical analysis. For this reason, we cannot evaluate the rate of colonization in each SAD. Concerning the risk of developing PcP, no P. jirovecii-positive PCR patients had PcP at 1 year of follow-up, but the level of immunosuppressant treatment was significantly reduced. Only three patients were screened during the follow-up, so we cannot be sure that colonization persisted. In a study on patients with RA, Mori et al. [34] found PcP in 3/9 patients colonized with P. jirovecii and recommended prophylaxis in these patients before any introduction of immunosuppressive therapy. In contrast to the situation in HIV-infected patients, the risk factors for PcP in SAD have not yet been sufficiently clearly defined, making it difficult to put forward recommendations on the appropriate point to apply prophylaxis. Recently, PcP has been described in patients on biotherapy [41, 42] . An awareness of SAD patients' P. jirovecii colonization status may be useful before the prescription of biotherapy in order to identify individuals who are more likely to benefit from PcP prophylaxis.
In conclusion, we found a high prevalence of P. jirovecii colonization among SAD patients (16%), which appears largely attributable to induced immunosuppression. Given the high level of P. jirovecii colonization, the severity of PcP in this population and the availability of a simple, non-invasive screening procedure, screening for P. jirovecii colonization could be recommended in all patients with SAD receiving immunosuppressant treatment. Furthermore, in the event of P. jirovecii colonization, the prescription of prophylactic treatment could be discussed before any escalation of therapy.
Rheumatology key messages
. Pneumocystis jirovecii colonization prevalence is high among patients with systemic autoimmune diseases. . Pneumocystis jirovecii colonization in these patients is in relation to treatment-induced immunodepression. . In the presence of Pneumocystis colonization, prophylactic treatment must be discussed before escalation of immunosuppressive medication.
